Background: Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions lead to the transcription of chimeric TRK proteins with overexpressed kinase function; this confers oncogenic potential across several tumor types. Entrectinib is a central nervous system (CNS)-active, potent inhibitor of TRKA/B/C and ROS1. We show integrated efficacy and safety analyses from entrectinib clinical trials. Methods: Patients (pts) with locally advanced/metastatic NTRK-fusion positive (fp) tumors confirmed by nucleic acid-based methods and enrolled in global (>150 sites, 15 countries) phase 1/2 entrectinib trials (ALKA, STARTRK-1, STARTRK-2; EudraCT 2012-000148-88; NCT02097810; NCT02568267) were included. Tumors were assessed after cycle 1 (4 wk) then every 8 wk. Scans underwent blinded independent central review (BICR) using RECISTv1.1. Primary endpoints: overall response rate (ORR); duration of response (DOR) by BICR. Secondary endpoints: progression-free survival (PFS), overall survival (OS) in pts with and without baseline CNS disease; safety. Results: The efficacy-evaluable population comprises 54 adult pts with advanced/metastatic NTRK-fp solid tumors (10 tumor types, >19 histopathologies), including pts with baseline CNS metastases. After 15.5 mo follow-up, BICR ORR was 57.4% (95% CI 43.2-70.8), complete responses n ¼ 4 (7.4%); responses seen in all tumor types. Median BICR DOR: 10.4 mo (95% CI 7.1-NR); median BICR PFS: 11.2 mo (95% CI 8.0-14.9); median OS: 20.9 mo (95% CI 14.9-NR). Per baseline CNS status (investigator assessed), median BICR PFS was 12.0 mo (95% CI 8.7-15.7) and 7.7 mo (95% CI 4.7-NR) for patients without (n ¼ 42) and with CNS disease (n ¼ 12), respectively. In the safety population (355 pts who received entrectinib across clinical trials), most treatment-related AEs were grade 1-2 and managed with dose reduction (27.3%); few pts discontinued (3.9%) due to treatment-related AEs. Conclusions: In this multicenter, pooled analysis of global clinical trials, entrectinib was well tolerated overall and induced clinically meaningful, durable systemic responses in pts with NTRK-fp solid tumors, type agnostic, with and without CNS disease. Clinical trial identification: EudraCT: 2012-000148-88; NCT02097810; NCT02568267. Legal entity responsible for the study: F. Hoffmann-La Roche. Funding: Ignyta, Inc., a wholly owned subsidiary of F. Hoffmann-La Roche Ltd. Background: There is mounting evidence that supports the inclusion of adolescents (12-17 years) in adult early phase trials, without requiring preceding specific paediatric trials. However, only few adult early phase trials currently include adolescents. On the other hand, the classical arbitrary upper age limit in paediatric trials (18 or 21 years old), hinders appropriate access to trials to young adults (19-25 years) with paediatric disease types. Methods: Review of all phase I/II trials opened in our institution for solid tumours/ lymphomas, from 01/01/2012 to 31/12/2017. Systematic analysis of each protocol/synopsis by three independent (1 medical, 1 adolescent/young adult, 1 paediatric) oncologists, with the main objective to describe the current inclusion of adolescents in adult trials and young adults in paediatric trials. Results: During 6years, overall 465 phase 1/2 trials were open. Adolescents (12-17 years) were included in 65 trials (15%): 61/62 (98%) paediatric trials and 4/403 (1%) adult trials. In 11/403 (3%) adult trials, lower age limit was 15/16 years. Concerning the 389 trails that were not open for recruitment of adolescents, this population could have been potentially included in 212/389 (55%) trials. 28/389 (7%) trials targeted tumour types that are frequently found in adolescents such as sarcoma, lymphoma and germ cell tumours. Concerning the inclusion of young adults (19-25 years) in paediatric trials, 36 of the 62 paediatric trials did not recruit this age group (upper age limit 18 years in 22 trials, 21 years in 13 trials), while 10 of these (28%) trials targeted cohorts of tumour types that can be also found in this age group. 552 patients (12-25years) had progressive disease during this period, 290 were 12-17years and 262, 18-25years. 403 were included in an early phase trial. Conclusions: Our data highlight the significant lack of adapted trials for the adolescent/young adult cancer population. A new lower age limit of 12 years for adult trials and an upper age limit of 25years for paediatrics trials should be individually discussed taken into account current evidence and international recommendations and would allow to improve the access to innovative treatment for these patients.
Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: A reality or a myth?
A. Vozy Background: There is mounting evidence that supports the inclusion of adolescents (12-17 years) in adult early phase trials, without requiring preceding specific paediatric trials. However, only few adult early phase trials currently include adolescents. On the other hand, the classical arbitrary upper age limit in paediatric trials (18 or 21 years old), hinders appropriate access to trials to young adults (19-25 years) with paediatric disease types. Methods: Review of all phase I/II trials opened in our institution for solid tumours/ lymphomas, from 01/01/2012 to 31/12/2017. Systematic analysis of each protocol/synopsis by three independent (1 medical, 1 adolescent/young adult, 1 paediatric) oncologists, with the main objective to describe the current inclusion of adolescents in adult trials and young adults in paediatric trials. Results: During 6years, overall 465 phase 1/2 trials were open. Adolescents (12-17 years) were included in 65 trials (15%): 61/62 (98%) paediatric trials and 4/403 (1%) adult trials. In 11/403 (3%) adult trials, lower age limit was 15/16 years. Concerning the 389 trails that were not open for recruitment of adolescents, this population could have been potentially included in 212/389 (55%) trials. 28/389 (7%) trials targeted tumour types that are frequently found in adolescents such as sarcoma, lymphoma and germ cell tumours. Concerning the inclusion of young adults (19-25 years) in paediatric trials, 36 of the 62 paediatric trials did not recruit this age group (upper age limit 18 years in 22 trials, 21 years in 13 trials), while 10 of these (28%) trials targeted cohorts of tumour types that can be also found in this age group. 552 patients (12-25years) had progressive disease during this period, 290 were 12-17years and 262, 18-25years. 403 were included in an early phase trial. Conclusions: Our data highlight the significant lack of adapted trials for the adolescent/young adult cancer population. A new lower age limit of 12 years for adult trials and an upper age limit of 25years for paediatrics trials should be individually discussed taken into account current evidence and international recommendations and would allow to improve the access to innovative treatment for these patients. Legal entity responsible for the study: Gaspar Nathalie. 
